Friedman, G K
Nan, L
Haas, M C
Kelly, V M
Moore, B P
Langford, C P
Xu, H
Han, X
Beierle, E A
Markert, J M
Cassady, K A
Gillespie, G Y
Article History
Received: 25 June 2014
Revised: 22 October 2014
Accepted: 30 October 2014
First Online: 27 November 2014
Change Date: 2 April 2015
Change Type: Correction
Change Details: This article has been corrected since advance online publication and an erratum is also printed in this issue
Competing interests
: Dr Markert and Dr Gillespie are founders of and own stock and stock options (<7% interest) in Catherex Inc. and in Aettis Inc., biotechnology companies that are developing other oncolytic HSV that are not the subject of this current investigation. They serve as consultants for Catherex Inc. as well. Dr Gillespie currently serves as one of five unpaid members of the Board of Directors for Catherex Inc. The virus used in this study is not licensed by either company or the subject of any company plans for clinical use. Dr Gillespie has served as a paid advisor to the Program Project at the Ohio State University that seeks to find improved methods for the application of oncolytic HSV to treat localized and metastatic cancers. This is generally, but not specifically, related to the subject matter of this investigation.